Inclusion Criteria:  Active clinical diagnosis and OCT confirmation of one of the following retinal disorders: exudative age-related macular degeneration (AMD), diabetic macular edema (DME), or branch retinal vein occlusion (BRVO) and, in the opinion of the Investigator, requires treatment with an anti-VEGF therapy  Exclusion Criteria:  Previous use of approved anti-VEGF or Avastin® within 4 weeks preceding randomization Previous use of Beovu® Macular edema due to something other than exudative AMD, DME or BRVO, in the study eye History of inadequate response to previous intravitreal anti-VEGF therapy History of any intraocular or periocular corticosteroid injection or implant, in the study eye Laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within 1-month preceding randomization Any concurrent intraocular condition in the study eye that may require medical or surgical intervention or contribute to vision loss during the study period Active intraocular inflammation in the study eye Current vitreous hemorrhage in the study eye Polypoidal choroidal vasculopathy (PCV) in the study eye History of idiopathic, infectious or autoimmune-associated uveitis in either eye Current ocular or periocular infection, such as conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye Uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥30 mmHg despite treatment with anti-glaucoma medication) Premenopausal women not using adequate contraception Current treatment for active systemic infection Known allergy to any component of the study drug , not amenable to treatment